ZA200504053B - Method for the prevention of malaria - Google Patents
Method for the prevention of malaria Download PDFInfo
- Publication number
- ZA200504053B ZA200504053B ZA200504053A ZA200504053A ZA200504053B ZA 200504053 B ZA200504053 B ZA 200504053B ZA 200504053 A ZA200504053 A ZA 200504053A ZA 200504053 A ZA200504053 A ZA 200504053A ZA 200504053 B ZA200504053 B ZA 200504053B
- Authority
- ZA
- South Africa
- Prior art keywords
- sporozoites
- plasmodium
- vaccine
- composition
- malaria
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title claims description 71
- 238000000034 method Methods 0.000 title claims description 42
- 230000002265 prevention Effects 0.000 title description 3
- 210000003046 sporozoite Anatomy 0.000 claims description 256
- 229960005486 vaccine Drugs 0.000 claims description 101
- 230000002238 attenuated effect Effects 0.000 claims description 80
- 241000223960 Plasmodium falciparum Species 0.000 claims description 64
- 244000045947 parasite Species 0.000 claims description 63
- 230000001681 protective effect Effects 0.000 claims description 56
- 208000015181 infectious disease Diseases 0.000 claims description 47
- 230000036039 immunity Effects 0.000 claims description 41
- 241000255925 Diptera Species 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 241000224016 Plasmodium Species 0.000 claims description 25
- 238000011161 development Methods 0.000 claims description 24
- 210000003079 salivary gland Anatomy 0.000 claims description 23
- 230000005855 radiation Effects 0.000 claims description 21
- 238000002255 vaccination Methods 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 18
- 238000001990 intravenous administration Methods 0.000 claims description 17
- 230000002458 infectious effect Effects 0.000 claims description 15
- 238000011081 inoculation Methods 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 14
- 210000003494 hepatocyte Anatomy 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 108010041986 DNA Vaccines Proteins 0.000 claims description 5
- 229940021995 DNA vaccine Drugs 0.000 claims description 5
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 5
- 241000223821 Plasmodium malariae Species 0.000 claims description 5
- 241001505293 Plasmodium ovale Species 0.000 claims description 5
- 241000223810 Plasmodium vivax Species 0.000 claims description 5
- 229940022005 RNA vaccine Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 241000256186 Anopheles <genus> Species 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 230000010558 Gene Alterations Effects 0.000 claims 7
- 230000007170 pathology Effects 0.000 claims 5
- 229940118768 plasmodium malariae Drugs 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 3
- 230000004075 alteration Effects 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000003053 immunization Effects 0.000 description 44
- 238000002649 immunization Methods 0.000 description 36
- 241000282412 Homo Species 0.000 description 33
- 241000223830 Plasmodium yoelii Species 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 27
- 230000018109 developmental process Effects 0.000 description 21
- 241000224017 Plasmodium berghei Species 0.000 description 19
- 238000000432 density-gradient centrifugation Methods 0.000 description 18
- 229940124735 malaria vaccine Drugs 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000011725 BALB/c mouse Methods 0.000 description 14
- 238000002224 dissection Methods 0.000 description 13
- 238000010253 intravenous injection Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 208000002476 Falciparum Malaria Diseases 0.000 description 10
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 10
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 9
- 241000283984 Rodentia Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000007918 intramuscular administration Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000013296 A/J mouse Methods 0.000 description 7
- 101710117490 Circumsporozoite protein Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010003399 Arthropod bite Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001524 infective effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 210000000973 gametocyte Anatomy 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940023143 protein vaccine Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 2
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000005469 Vivax Malaria Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282821 Hippopotamus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 101000726057 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 101900205473 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002348 hepatitis b surface antigen vaccine Drugs 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 108700041548 protozoan thrombospondin-related adhesive Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42791102P | 2002-11-20 | 2002-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504053B true ZA200504053B (en) | 2006-07-26 |
Family
ID=32326611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504053A ZA200504053B (en) | 2002-11-20 | 2005-05-19 | Method for the prevention of malaria |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1563301B1 (fr) |
| JP (1) | JP2006508988A (fr) |
| KR (1) | KR20050083941A (fr) |
| CN (1) | CN1934448B (fr) |
| AP (1) | AP1925A (fr) |
| AT (1) | ATE524735T1 (fr) |
| AU (1) | AU2003294482A1 (fr) |
| BR (1) | BR0316423A (fr) |
| CA (1) | CA2506696C (fr) |
| ES (1) | ES2371066T3 (fr) |
| HK (1) | HK1075936A1 (fr) |
| IL (1) | IL168651A (fr) |
| NZ (1) | NZ540719A (fr) |
| OA (1) | OA13012A (fr) |
| WO (1) | WO2004045559A2 (fr) |
| ZA (1) | ZA200504053B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG149058A1 (en) | 2003-12-19 | 2009-01-29 | Seattle Biomedical Res Inst | Live genetically attenuated malaria vaccine |
| US7722860B2 (en) * | 2004-12-03 | 2010-05-25 | Seattle Biomedical Research Institute | Live genetically engineered protozoan vaccine |
| US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
| WO2008094183A2 (fr) * | 2006-07-11 | 2008-08-07 | University Of Connecticut | Utilisation de souches de plasmodium conditionnelles exemptes de transporteurs de nutriments dans la vaccination anti-paludique |
| US11000580B2 (en) | 2010-12-27 | 2021-05-11 | Eng Hong Lee | Roadmap for controlling malaria |
| FR2978048B1 (fr) | 2011-07-20 | 2014-10-10 | Univ Paris Curie | Composition vaccinale contre le paludisme |
| EP3137106B1 (fr) * | 2014-05-02 | 2023-07-05 | Sanaria Inc. | Sporozoïtes infectieux de plasmodium cultivés in vitro |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2031468A1 (fr) * | 1989-12-08 | 1991-06-09 | Mitchell S. Gross | Vaccin contre la malaria |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| MXPA01008176A (es) * | 1999-02-18 | 2002-08-30 | Rmf Dictagene Sa | Vacuna contra el paludismo. |
| WO2009090269A2 (fr) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven, K.U.Leuven R & D | Marqueurs et procédés de diagnostic pour une métastase |
-
2003
- 2003-11-20 BR BR0316423-3A patent/BR0316423A/pt not_active IP Right Cessation
- 2003-11-20 JP JP2004554018A patent/JP2006508988A/ja active Pending
- 2003-11-20 EP EP03789967A patent/EP1563301B1/fr not_active Expired - Lifetime
- 2003-11-20 CA CA2506696A patent/CA2506696C/fr not_active Expired - Fee Related
- 2003-11-20 KR KR1020057009184A patent/KR20050083941A/ko not_active Application Discontinuation
- 2003-11-20 AP AP2005003332A patent/AP1925A/xx active
- 2003-11-20 WO PCT/US2003/037498 patent/WO2004045559A2/fr active Application Filing
- 2003-11-20 CN CN2003801075999A patent/CN1934448B/zh not_active Expired - Fee Related
- 2003-11-20 ES ES03789967T patent/ES2371066T3/es not_active Expired - Lifetime
- 2003-11-20 NZ NZ540719A patent/NZ540719A/en not_active IP Right Cessation
- 2003-11-20 AU AU2003294482A patent/AU2003294482A1/en not_active Abandoned
- 2003-11-20 OA OA1200500157A patent/OA13012A/en unknown
- 2003-11-20 AT AT03789967T patent/ATE524735T1/de not_active IP Right Cessation
-
2005
- 2005-05-18 IL IL168651A patent/IL168651A/en active IP Right Grant
- 2005-05-19 ZA ZA200504053A patent/ZA200504053B/en unknown
- 2005-11-14 HK HK05110198.4A patent/HK1075936A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE524735T1 (de) | 2011-09-15 |
| EP1563301A4 (fr) | 2007-07-11 |
| IL168651A (en) | 2011-04-28 |
| CA2506696A1 (fr) | 2004-06-03 |
| ES2371066T3 (es) | 2011-12-27 |
| CA2506696C (fr) | 2013-05-14 |
| AP2005003332A0 (en) | 2005-06-30 |
| CN1934448B (zh) | 2012-01-11 |
| AP1925A (en) | 2008-12-08 |
| EP1563301B1 (fr) | 2011-09-14 |
| KR20050083941A (ko) | 2005-08-26 |
| CN1934448A (zh) | 2007-03-21 |
| AU2003294482A1 (en) | 2004-06-15 |
| EP1563301A2 (fr) | 2005-08-17 |
| NZ540719A (en) | 2009-07-31 |
| AU2003294482A2 (en) | 2005-08-25 |
| JP2006508988A (ja) | 2006-03-16 |
| OA13012A (en) | 2006-11-10 |
| WO2004045559A3 (fr) | 2004-08-12 |
| WO2004045559A2 (fr) | 2004-06-03 |
| HK1075936A1 (en) | 2005-12-30 |
| BR0316423A (pt) | 2005-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050208078A1 (en) | Methods for the prevention of malaria | |
| US20050220822A1 (en) | Methods for the prevention of malaria | |
| Vaughan et al. | Genetically engineered, attenuated whole-cell vaccine approaches for malaria | |
| Laurens | The promise of a malaria vaccine—are we closer? | |
| Thera et al. | Vaccines for malaria: how close are we? | |
| Richie et al. | Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines | |
| Luke et al. | Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine | |
| Itsara et al. | The development of whole sporozoite vaccines for Plasmodium falciparum malaria | |
| Sinden | A biologist’s perspective on malaria vaccine development | |
| Webster et al. | Progress with new malaria vaccines | |
| Zheng et al. | Prospects for Malaria Vaccines: Pre‐Erythrocytic Stages, Blood Stages, and Transmission‐Blocking Stages | |
| Heppner | The malaria vaccine–status quo 2013 | |
| Epstein et al. | The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review | |
| Syaifudin et al. | The feasibility of gamma irradiation for developing malaria vaccine | |
| ZA200504053B (en) | Method for the prevention of malaria | |
| Nunes-Cabaço et al. | Five decades of clinical assessment of whole-sporozoite malaria vaccines | |
| Mikolajczak et al. | Preerythrocytic malaria vaccine development | |
| Gardner et al. | DNA vaccines against malaria: immunogenicity and protection in a rodent model | |
| Hassert et al. | Memory CD8+ T cell‐mediated protection against liver‐stage malaria | |
| Todryk et al. | Building better T‐cell‐inducing malaria vaccines | |
| Etefia et al. | Malaria vaccine development: challenges and prospects | |
| Hedstrom et al. | The development of a multivalent DNA vaccine for malaria | |
| Frevert et al. | Arrest in the liver-a genetically defined malaria vaccine | |
| Kristoff | Malaria stage-specific vaccine candidates | |
| Tandel et al. | Application of radiation technology: a novel vaccine approach to induce protective immunity against malaria infection |